The Methylation Bottleneck: Preventing Sirtuin Inhibition in NAD+ Therapy

A common mistake in the administration of NAD+ precursors is the neglect of the methylation cycle. When you supplement with NMN or NR, the body converts these into NAD+, but it also produces a byproduct called Nicotinamide (NAM). While NAM can be recycled via the salvage pathway, an excess of it must be methylated and excreted through the urine to prevent it from inhibiting Sirtuin activity. This process of methylation requires methyl donors—primarily S-adenosylmethionine (SAMe). If an individual is aggressively boosting NAD+ without supporting their methylation capacity, they risk depleting their methyl pool.

This has profound implications for health: SAMe is required for the synthesis of neurotransmitters (like dopamine and serotonin), the regulation of gene expression via DNA methylation, and the detoxifying of homocysteine. A 'methyl-trap' occurs when the body prioritises the clearance of excess nicotinamide over these vital functions. High homocysteine levels, a known risk factor for cardiovascular disease and cognitive decline, can be an unintended consequence of poorly managed NAD+ supplementation. This is the 'methylation bottleneck' that mainstream supplement guides rarely mention. To mitigate this risk, evidence-based protocols suggest co-supplementing with methyl donors such as Trimethylglycine (TMG/Betaine) or methylcobalamin (B12) and methylfolate.

This ensures that the salvage pathway remains fluid and that the SIRT-inhibiting byproduct, nicotinamide, is efficiently processed without compromising other essential biochemical pathways. Furthermore, monitoring one's MTHFR status can provide a personalised roadmap for how much methyl support is required. By addressing the methylation bottleneck, we ensure that the pursuit of cellular longevity does not inadvertently compromise neurological health or cardiovascular integrity.